Navigation Links
Effective Rx thwarted for deadly opioid epidemic
Date:6/21/2013

WASHINGTON, June 21, 2013 /PRNewswire-USNewswire/ -- State governments and insurance companies are increasingly restricting the use of effective, FDA-approved medications that could help reverse the epidemic of opioid addiction and overdose deaths, according to the most comprehensive reports on opioid addiction medications released today by the American Society of Addiction Medicine (ASAM).

Approximately 4 million U.S. residents are addicted to prescription and illegal opioids. Nearly 15,000 people die every year from overdoses involving pain medications, more than die in drunk driving car crashes. Addiction is a treatable chronic disease with treatment success and relapse rates comparable to other chronic diseases such as diabetes and hypertension. Opioid addiction is best managed with a combination of treatments, including behavioral interventions and medications. The FDA has approved three principal medications for treating opioid addiction: buprenorphine, methadone and naltrexone.

"These reports show that we could be saving lives and effectively treating the disease of addiction if state governments and insurance companies remove roadblocks to the use of these medications," said Stuart Gitlow, MD, President of ASAM. "Treatment professionals need every evidence-based tool available to end suffering from this chronic disease. State lawmakers and insurance company administrators would never deny needed medication to people suffering from other chronic diseases, like diabetes and hypertension. But it happens every day to people with addiction."

Strong evidence of effectiveness
The report on effectiveness of opioid medications, conducted by the Treatment Research Institute, examined 642 unique studies that evaluated buprenorphine, methadone, oral naltrexone and injectable naltrexone. The report found that these medications show substantive evidence of effectiveness and safety. They're shown to decrease the frequency and quantity of drug use, withdrawal and craving, infectious diseases, criminal behavior and overdose, and to improve social functioning.

The medications show clear evidence of effectiveness only when used as long-term treatment, much like insulin for diabetes. There is very little indication of short-term benefit.

These medications also are cost-effective, with costs for maintenance medications to treat opioid addiction roughly comparable to costs for diabetes medications.

Complex, arbitrary restrictions
The reports on state Medicaid and insurance company restrictions were conducted through surveys by The AVISA Group and the Treatment Research Institute. The researchers reported that insurance company managers were reluctant to respond to questions about opioid medication restrictions.

The state Medicaid coverage report showed that while every state covers at least one FDA-approved opioid addiction medication, restrictions vary widely from state to state and often create de facto denial of access. Coverage limits for lifetime benefits and daily dosages are common. Restrictive prior authorizations add another level of obstacles. Information about restrictions and compliance regarding these medications is very difficult to obtain from state agencies. Many states require other treatments to fail first before addiction medications are covered.

Similarly, private insurance companies' restrictions on opioid addiction medications are complex, contradictory and often arbitrary. Insurance companies widely use utilization management techniques like prior authorization that impedes the use of addiction medications, and they also limit coverage on quantities of medication.

Dosage and quantity restrictions on opioid addiction medications by insurance companies and state Medicaid programs contravene recommendations from professional medical associations and the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). These restrictions may risk patient safety and lead to suffering and death with no clear therapeutic objective. With no single national practice guideline on use of pharmacotherapies for opioid addiction, states and payers are filling in a much-needed gap.

Denial of access 'unethical'
"The fact that patients are frequently denied access to the full spectrum of treatment options for addiction is unethical and would constitute malpractice in other medical specialties and chronic disease treatment," said Thomas McLellan, a report author who is CEO of the Treatment Research Institute and former Deputy Director of the White House Office of National Drug Control Policy. "Treatment of addiction must be raised to the same medical and ethical standards as treatment for other chronic diseases. This needs to be acknowledged by the treatment community, medical specialties, insurance companies and all levels of government."

According to the reports, none of the medications by themselves can be considered effective treatments for opioid dependence. All medications are designed for use as part of comprehensive treatment strategies that usually include counseling, social supports and behavioral change strategies. But research shows they can be vital treatment components that raise treatment success rates.

"Medical science supports the use of addiction medications to effectively treat the disease of addiction," Dr. Gitlow said. "This science must be the basis of state policies, insurance coverage and national standards for the treatment of addiction. We want to work with public and private payers to identify models of patient access that can be shared broadly. Restrictions by states and insurance companies make no sense when opioid addiction and overdose deaths have grown into a national epidemic."


'/>"/>
SOURCE American Society of Addiction Medicine
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Natural Process Green Coffee Bean Extract Promises Safe, Effective Weight Loss Without Stimulants or Unhealthy Additives
2. Belrose Pharma Acquires Enzons Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies
3. New drug proving effective in attacking advanced prostate cancer
4. Effective Rx thwarted for deadly opiate epidemic
5. Daily 10 milligram dose of S-equol reduces menopausal symptoms effectively without impacting thyroid and sex hormones
6. Aetna, Cardinal Health Specialty Solutions Alliance Delivers More Cost-Effective, Patient-Centered Cancer Care
7. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
8. BioElectronics Continues FDA Clearance Campaign to Bring Chronic Pain Sufferers Safe, Effective, Inexpensive, Drug-Free Pain Therapy
9. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
10. Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness
11. The MED Group Announces New Agreement with CareCentrix Effective May 1, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
(Date:5/6/2017)... 2017  May is Stroke Awareness Month and Omron ... important methods to prevent a stroke: monitor and manage ... Control and Prevention, undetected and uncontrolled hypertension is a ... global leader in personal heart health technology, recently evolved ... attack and stroke and is advancing a national public ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... ... Myers Jackson is well known for auctioning homes that people move and ... the planet. The luxury home market is alive and well and there are mansions ... of “11 Spyglass Hill Auction will enlighten you on the dynamics of how to ...
(Date:5/24/2017)... Lake Orion, Michigan (PRWEB) , ... ... ... is a disease affecting the female reproductive tract in which the endometrial ... the pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, painful ...
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan ... dentistry options for its patients on Long Island, New York. , Holistic ... being, and is one of the biggest trends in dentistry today. , ...
(Date:5/24/2017)... ... 2017 , ... The CFOs included on this list lead ... the nation and help their organizations navigate the challenges in healthcare today. These ... developing successful hospital and health system strategy. , Becker's Hospital Review has published ...
Breaking Medicine News(10 mins):